Key result
VEGF-A mRNA-loaded extracellular vesicles improve neovascularization and LV function without significant immunogenicity in mice.
Why the study?
Does extracellular vesicle-mediated VEGF-A mRNA delivery improve neovascularization and function in mouse models of ischaemic injury?
Does extracellular vesicle-mediated VEGF-A mRNA delivery improve neovascularization and function in mouse models of ischaemic injury?
Answers are grounded in this paper and cite their sources.
Extracellular vesicle-mediated delivery of VEGF-A mRNA improves neovascularization and cardiac/limb function in murine ischaemia models with lower immunogenicity than viral or lipid nanoparticle vectors.
BACKGROUND AND AIMS: Lackluster results from recently completed gene therapy clinical trials of VEGF-A delivered by viral vectors have heightened the need to develop alternative delivery strategies. This study aims to demonstrate the pre-clinical efficacy and safety of extracellular vesicles (EVs) loaded with VEGF-A mRNA for the treatment of ischaemic vascular disease. METHODS: After encapsulation of full-length VEGF-A mRNA into fibroblast-derived EVs via cellular nanoporation (CNP), collected VEGF-A EVs were delivered into mouse models of ischaemic injury. Target tissue delivery was verified by in situ analysis of protein and gene expression. Functional rescue was confirmed by in vivo imaging and histology. The safety of single and serial delivery was demonstrated using immune-based assays. RESULTS: VEGF-A EVs were generated with high mRNA content using a CNP methodology. VEGF-A EV administration demonstrated expression of exogenous VEGF-A mRNA by in situ RNA hybridization and elevated protein expression by western blot, microscopy, and enzyme-linked immunosorbent assay. Mice treated with human VEGF-A EVs after femoral or coronary artery ligation exhibited heightened neovascularization in ischaemic tissues with increased arterial perfusion and improvement in left ventricular function, respectively. Serial delivery of VEGF-EVs in injured skin showed improved wound healing with repeat administration. Importantly, as compared with adeno-associated viral and lipid nanoparticle VEGF-A gene therapy modalities, murine VEGF-A EV delivery did not trigger innate or adaptive immune responses at the injection site or systemically. CONCLUSIONS: This study demonstrated that VEGF-A EV therapy offers efficient, dose-dependent VEGF-A protein formation with low immunogenicity, resulting in new vessel formation in murine models of ischaemic vascular disease.
No takes yet. Share an insight, caveat, or question.
You et al. (2025) studied Ischaemic vascular disease. Extracellular vesicles loaded with VEGF-A mRNA vs. Adeno-associated viral and lipid nanoparticle VEGF-A gene therapy was evaluated on Neovascularization, arterial perfusion, left ventricular function, and immunogenicity. Extracellular vesicles loaded with VEGF-A mRNA improved neovascularization and left ventricular function in murine models of ischaemic injury without triggering significant immune responses.
Synapse has enriched 10 related papers. Consider them for comparative context: